5Jung H S,Lee J H,Chun E M. Predictors of long-term mortality after hospitalization for acute exacerbation of COPD[J].Tuberc Respir Dis,2006,(02):205-214.
6Joppa P,Petrasova D,Stancak B. Systemic inflammation in patients with COPD and pulmonary hypertension[J].Chest,2006,(02):326-333.
7Chaouat A,Savale L,Chouaid C. Role for interleukin6 in COPD-related pulmonary hypertension[J].Chest,2009,(03):678-687.
8Stolz O,Christ-Crain M,Nils G. Plasma ProAdrenomedullin But Not Plasma Pro-Endothelin Predicts Survival in Exacerbations of COPD[J].Chest,2008,(02):263-272.doi:10.1378/chest.08-0047.
9The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and The European Respiratory Society (ERS),the International Society of Heartand Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment Of pulmonary hypertension[J].European Heart Journal,2009,(20):2493-2537.
10ddahibi S,Chaouat A,Tu L. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease[J].PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY(PATS),2006,(06):475-476.
7BATHOORN E. LIESKER JJ, POSTMA DS, et al. Anti- inflammatory effects of combined budesonide/formoterol in COPD exacerbations [ J ]. COPD, 2008,5 (5) : 282-290.
8UM SJ, LAM S, COXSON H, et al. Budesonide/formoterol enhances the expression of pro surfactant protein-B in lungs of COPD oatients[J]. PLoS One. 2013.8(12) :e83881.
9HODGE S, HODGE G, HOLMES M, et al. Increased CD8 T- cell granzyme B in COPD is suppressed by treatment with low- dose azithromycin [ J ]. Respirology, 2015,20 ( 1 ) : 95-100.
10NOTEBOOM B, JENKINS S, MAIORAN A, et al. Comorbidities and medication burden inpatients with chronic obstructive pulmonary disease attending pulmonary rehabilitation [J]. Cardiopulm Rehabil Prev, 2014,3 (4) : 75-79.
